Seroprevalence of SARS‐CoV‐2 in pediatric hematology‐oncology patients
Pediatric Blood & Cancer · 2024
DOI: 10.1002/pbc.31212 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pediatric Blood & Cancer, 2024. Verfasst von Vivian Phan und 6 weiteren Autor:innen. Beteiligte Einrichtung: Center for Cancer and Blood Disorders, Pediatric Specialists of Virginia, Fairfax, Virginia, USA. Hauptthemen laut MEDLINE: COVID-19, SARS-CoV-2, Antibodies, Viral. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Inova Seed: InovaHealthSystem.
Abstract (Originalsprache)
Background
The COVID‐19 pandemic disproportionately affected persons with underlying medical conditions. SARS‐CoV‐2 infection susceptibility and vaccine effectiveness in pediatric hematology‐oncology patients were unknown.
Methods
From February to July 2022, anti‐spike and anti‐nucleocapsid Ig were assayed in 354 pediatric hematology‐oncology subjects, including 53 oncology patients receiving chemotherapy (cancer), 150 patients with sickle cell disease (SCD), and 151 benign consult and long‐term follow‐up patients (controls). Participants completed a questionnaire.
Results
Frequencies of COVID‐19 infection, defined by positive PCR/antigen test or anti‐nucleocapsid Ig, were 62% in cancer, 71% in SCD, 52% in controls, with SCD statistically different than controls ( p = .001). Infection was associated with COVID‐19 exposure, Hispanic/Latino or Black/African American ethnicity, multi‐family dwelling, sports participation; COVID‐19 booster decreased association with infection. In COVID‐19‐positive cancer patients, 58% had positive anti‐nucleocapsid and 76% had positive anti‐spike (≥10 U/mL), compared to essentially 100% seroconversion in SCD and controls ( p < .0001, p = .01, respectively). Infection led to high anti‐spike (≥2500 U/mL) in 12% cancer, 14% SCD, and 15% controls ( p = .93). Vaccination resulted in anti‐spike positivity in 90% cancer, 100% SCD, and 100% controls ( p = .06), and in high anti‐spike in 20% cancer, 47% SCD, and 41% controls ( p = .36). Of boosted subjects, one of two cancer, 6/6 SCD, and 19/19 controls exhibited high anti‐spike.
Conclusions
Cancer patients demonstrated similar SARS‐CoV‐2 infection frequency as controls, but diminished antibody response to infection and vaccination. SCD patients exhibited seroconversion indistinguishable from controls. Vaccination was associated with higher frequency of high anti‐spike than infection; vaccination plus booster was most effective in eliciting high anti‐spike antibody detectable beyond 90 days.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Cancer and Blood Disorders, Pediatric Specialists of Virginia, Fairfax, Virginia, USA.
- Inova Children's Hospital, Falls Church, Virginia, USA.
- Inova Schar Heart and Vascular, Fairfax, Virginia, USA.
- University of Virginia, Charlottesville, Virginia, USA.
- George Washington University School of Medicine, Washington, District of Columbia, USA.
ORCID-Profile: Elizabeth Yang
Förderung
- Inova Seed: InovaHealthSystem
Zitieren
APA
Phan, V., Richards, T., Kang, K., Sheridan, M., Levorson, R., deFilippi, C., & Yang, E. (2024). Seroprevalence of SARS‐CoV‐2 in pediatric hematology‐oncology patients. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.31212
Vancouver
Phan V, Richards T, Kang K, Sheridan M, Levorson R, deFilippi C, et al. Seroprevalence of SARS‐CoV‐2 in pediatric hematology‐oncology patients. Pediatric Blood & Cancer. 2024. doi:10.1002/pbc.31212
BibTeX
@article{Phan2024,
author = {Phan, Vivian and Richards, Tiana and Kang, Keehyo and Sheridan, Michael and Levorson, Rebecca and deFilippi, Christopher and Yang, Elizabeth},
title = {Seroprevalence of SARS‐CoV‐2 in pediatric hematology‐oncology patients},
journal = {Pediatric Blood & Cancer},
year = {2024},
doi = {10.1002/pbc.31212}
}
EUVIMED